Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

The Zava acquisition will enable Hims & Hers to expand its footprint in the U.K. and launch operations in countries such as Germany, France, and Ireland, with other markets expected to follow soon.

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Tuesday after the company announced an acceleration of its global expansion through the acquisition of ZAVA.

The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.9%. This drop was much worse than the S&P 500’s 1.9% loss.

The company said the layoffs were unrelated to the regulatory change.

Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted.

Large-cap stocks were the worst performers last week, with declines up to 23%. Reasons include revenue misses, FDA bans, and Uber's stake monetization.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Stocks were moving lower to end the week as tariff concerns returned; however NVIDIA earnings next week may help investors climb the wall of worry

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth division introduced a monthly $200 price cap for weight-loss medications such as Wegovy and Zepbound, a move that could significantly disrupt pricing in the weight loss drug market. 

The UnitedHealth stock sell-off might have spooked investors in the medical sector, who are wondering if it will affect shares of Hims & Hers equally.

Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide subscription programs.

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.